Shares of Abbott Laboratories (NYSE: ABT ) may be up 10.7% since the start of 2013, but this stock has lagged behind the S&P 500 index and many of its health care peers, including Boston Scientific (NYSE: BSX ) and Johnson & Johnson. Abbott's next big catalyst will be its second-quarter results, which are set to be revealed tomorrow morning, but will earnings wow investors, or will they miss estimates and disappoint?
In the following video, health care analyst Max Macaluso explains the three main sections in tomorrow's report that investors should watch. Special attention should be paid to medical device sales, which weighed heavily on Abbott and other companies in this sector last quarter.
One of the most attractive parts of owning a health care stock like Abbott Labs is its dividend, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.